“…This has revolutionized the treatment of aortic stenosis, but also produced several unanswered questions with regard to valve durability, subclinical leaflet thrombosis, permanent pacemaker insertion with subsequent rehospitalization, the evolving role of TAVR in low-risk patients, and preparing future cardiac surgeons for practices that include transcatheter techniques. [3][4][5] Naturally, although transfemoral TAVR (TF-TAVR) is the preferred route, questions surrounding the ideal alternative access have persisted for those patients not suitable for TF-TAVR.…”